期刊文献+

替吉奥联合卡铂二线治疗晚期非小细胞肺癌的近期疗效观察 被引量:2

下载PDF
导出
摘要 观察替吉奥联合卡铂二线治疗晚期非小细胞肺癌的有效性和安全性。44例晚期非小细胞肺癌患者二线接受替吉奥联合卡铂方案化疗。化疗客观有效率(CR+PR)为11.4%,疾病控制率(CR+PR+SD)为59.1%。化疗后不良反应以骨髓抑制及胃肠道反应为主,未见其他严重不良反应。替吉奥联合卡铂方案二线治疗晚期非小细胞肺癌疗效确切,给药途径方便,耐受性较好,为晚期非小细胞肺癌的治疗提供了一种新的选择。
出处 《现代诊断与治疗》 CAS 2015年第20期4657-4658,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献8

二级参考文献73

  • 1余建和.以奈达铂为主联合方案治疗非小细胞肺癌的临床观察[J].药学与临床研究,2007,15(3):231-232. 被引量:5
  • 2Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S-1):a review.Oncologist,2002,7:288-323.
  • 3Hoff PM.The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines,UFT/leucovorin (ORZEL) and S-1:a review of their clinical development and therapeutic potential.Invest New Drugs,2000,18:331-342.
  • 4Fukushima M,Morita M,Ikeda K,et al.Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.Int J Mol Med,2003,12:839-844.
  • 5Kaira K,Sunaga N,Yanagitani N,et al.A phase Ⅰ dose-escalation study of S-1 plus carboplatin in patients with advanced non-smallcell lung cancer.Anticancer Drugs,2007,18:471-476.
  • 6Ohba T,Yamasaki T,Endo Y,et al.A phase Ⅰ study of TS-1plus carboplatin in patients with advanced non-small-cell lung cancer.J Chemother,2009,21:80-85.
  • 7Chikamori K,Kishino D,Takigawa N,et al.A phase Ⅰ study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.Lung Cancer,2008,62:126-132.
  • 8Kaira K,Sunaga N,Yanagitani N,et al.Phase Ⅰ study of oral s1 plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.Int J Radiat Oncol Biol Phys,2009,75:109-114.
  • 9Ishimoto O,Ishida T,Honda Y,et al.Phase Ⅰ study of daily S-1 combined with weekly irinotecan in patients with advanced nonsmall cell lung cancer.Int J Clin Oncol,2009,14:43-47.
  • 10Kaira K,Sunaga N,Yanagitani N,et al.Phase Ⅰ trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.Anticancer Drugs,2008,19:289-294.

共引文献57

同被引文献28

  • 1林丽珠,陶志广,周岱翰.WHO标准和RECIST在肺癌多中心疗效评价的比较[J].中国肿瘤临床,2006,33(5):253-255. 被引量:41
  • 2白春学.内科学[M].第8版.北京:人民卫生出版社,2013:3.
  • 3Schiller JH, Harrington D. Comparison of four chemothera- py regimens for advanced non-small cell lung cancer[J]. N. Engl J Med, 2002,346 : 92-98.
  • 4Zhou C,Wu YL,Chen G,et al. Erlotinib versus chemother- apy as first treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer[J]. Lancet Oncol,2011,12(8) :735-742.
  • 5Dansin E, Cousin S,Lauridant,et al. Bevacizumab in tho- racic oncology: Results and practical aspects[J]. Rev Pneu- mol Clin ,2013,69(3) : 159-169.
  • 6Zhang L,Ma S,Song X,et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer[J]. Lancet Oncol, 2012,13(5) :466-475.
  • 7Paz Ares L,de Marinis F,Dedin M,et al. Maintenance therapy with pcmetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer[J]. Lancet 0ncol,2012, 13(3): 247-255.
  • 8Fidias P M,Dakhi] S R,Lyss LP,et al. Phase III study of immediate compared with delayed docetaxel after front- line therapy with gemcitabine plus carboplatin in ad- vanced non-small cell lung caner[J]. Clin 0ncol,2009,27 (4) :591-598.
  • 9Ueno H,Loka T,Keda M,et al. Randomized phase III study of gemcitabine plus S-1,S-I alone,or gemcitabine alone in patients with !ocally advanced and metastatic pancreatic cancer in Japan and Taiwan:GEST study [J]. J Clin Oncol, 2012,31 : 1640-1648.
  • 10Yamamoto Y, Nishmrua R,Tanigawa T,et al. Efficacy and safety of S-1 mono-therapy for advanced or metastatic. breast cancer:An observational study by the Kumamoto Breast Caner Cooperative Group(KBCCG)[J]. Gan To Ka- gaku Ryoho, 2014, 41 (10) : 1221 - 1225.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部